[go: up one dir, main page]

ES2616022T3 - Composiciones farmacéuticas de curcumina - Google Patents

Composiciones farmacéuticas de curcumina Download PDF

Info

Publication number
ES2616022T3
ES2616022T3 ES11824671.9T ES11824671T ES2616022T3 ES 2616022 T3 ES2616022 T3 ES 2616022T3 ES 11824671 T ES11824671 T ES 11824671T ES 2616022 T3 ES2616022 T3 ES 2616022T3
Authority
ES
Spain
Prior art keywords
oil
surfactant
solvent
propylene glycol
curcumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11824671.9T
Other languages
English (en)
Inventor
Bakulesh Mafatlal Khamar
Ashish Premkumar Gogia
Chirag Chandrakant Goda
Dinesh Balkunje Shenoy
Rajneesh Ramesh Shrivastava
Vandana Bharat Patravale
Indravadan Ambalal Modi
Ritu Nitin Laddha
Imran Ahmad Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cadila Pharmaceuticals Ltd
Original Assignee
Cadila Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Pharmaceuticals Ltd filed Critical Cadila Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2616022T3 publication Critical patent/ES2616022T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica estable de curcumina que comprende aceite, disolvente, tensioactivo y, opcionalmente, antioxidante, estando la proporción del aceite con respecto al disolvente, del tensioactivo con respecto al disolvente y del tensioactivo con respecto a la curcumina en el intervalo de 0,83 a 10, de 1 a 60 y de 3 a 15, respectivamente, con curcumina en el intervalo del 2 al 20 % p/p, en la que (i) el aceite se selecciona entre: (1) aceite de coco fraccionado, triglicérido caprílico/cáprico o un aceite que contiene triglicéridos de ácidos grasos, preferentemente triglicéridos de ácidos grasos de cadena media; (2) miristato de isopropilo, palmitato de isopropilo, linoleato de etilo o un aceite que contiene ésteres de oleato de etilo de ácidos grasos y alcanoles monovalentes; (3) dicaprilato de propilenglicol, dilaurato de propilenglicol o un aceite que contiene diésteres de ácidos grasos de propilenglicol; (ii) el tensioactivo se selecciona entre polisorbato, vitamina E TPGS y Cremophor®; y (iii) el disolvente se selecciona entre glicofurol, polietilenglicol, glicerol, polipropilenglicol, propilenglicol, glicerina, N-metil-2-pirrolidona y alcohol etílico o mezcla de los mismos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11824671.9T 2010-09-15 2011-09-12 Composiciones farmacéuticas de curcumina Active ES2616022T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2553MU2010 2010-09-15
INMU25532010 2010-09-15
PCT/IB2011/053974 WO2012035480A2 (en) 2010-09-15 2011-09-12 Pharmaceutical compositions of curcumin

Publications (1)

Publication Number Publication Date
ES2616022T3 true ES2616022T3 (es) 2017-06-09

Family

ID=45832022

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11824671.9T Active ES2616022T3 (es) 2010-09-15 2011-09-12 Composiciones farmacéuticas de curcumina

Country Status (4)

Country Link
US (1) US9474727B2 (es)
EP (1) EP2616053B1 (es)
ES (1) ES2616022T3 (es)
WO (1) WO2012035480A2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046978A1 (es) * 2017-09-05 2019-03-14 Universidad De Chile Método para obtener nanoestructuras con carotenoides y nanoestructuras obtenidas
RU2808324C2 (ru) * 2019-02-11 2023-11-28 Джозеф ХАЛСТЕД Терапевтически применимые высокодозированные безводные растворы куркуминоидов

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202012013584U1 (de) * 2012-10-22 2018-01-15 Briu Gmbh Pharmazeutische Formulierung enthaltend Curcumin
US9517249B2 (en) 2012-11-26 2016-12-13 Access Business Group International Llc Antioxidant dietary supplement and related method
US11185507B2 (en) 2014-10-08 2021-11-30 Boston Biopharm Inc. Compositions and methods for increasing the bioavailability of one or more compounds
US10085951B2 (en) 2014-12-11 2018-10-02 Designs For Health, Inc. Curcuminoid formulations and related methods of treatment
ES2895851T3 (es) 2016-04-01 2022-02-22 Trioptotec Gmbh Dispersión de fotosensibilizador y uso de la misma
CN106667912A (zh) * 2017-02-08 2017-05-17 何德海 一种姜黄素纳米乳液的制备方法
CN110538167A (zh) * 2018-05-29 2019-12-06 冉文萍 姜黄素组合物及其制备方法和用途
CN110960516B (zh) * 2018-09-27 2023-01-06 广州汝丽多食品科技有限公司 一种姜黄素复合物及其制备方法
AU2019365596B2 (en) 2018-10-23 2025-07-03 Lyrus Life Sciences Pvt. Ltd. Formulation comprising water soluble particles of a non-curcuminoid and a curcuminoid
WO2020181256A1 (en) * 2019-03-06 2020-09-10 Renibus Therapeutics, Inc. Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same
WO2021016576A1 (en) * 2019-07-25 2021-01-28 Skin Medicinals LLC Topical compositions
CN110693833A (zh) * 2019-10-31 2020-01-17 上海交通大学医学院附属新华医院 一种用超浓乳液制备纳米姜黄素复合制剂的方法
AU2021373070B2 (en) 2020-11-09 2023-08-24 Albert Einstein College Of Medicine Transdermal delivery formulations
CN115176989A (zh) * 2022-07-12 2022-10-14 河南中大恒源生物科技股份有限公司 一种透明姜黄素油溶液及其制备方法和应用
WO2025107048A1 (pt) * 2023-11-21 2025-05-30 Makrofarma Química Farmacêutica Ltda Composição farmacêutica a base de curcuminóides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
CN100352430C (zh) 2005-03-09 2007-12-05 山东大学 姜黄素自微乳化制剂及其制备方法
PL1993365T3 (pl) 2006-03-06 2013-10-31 Univ California Preparaty z biodostępnych kurkuminoidów do leczenia choroby alzheimera oraz innych zaburzeń powiązanych z wiekiem
WO2010010431A1 (en) 2008-07-24 2010-01-28 National Institute Of Pharmaceutical Education And Research Self-nano-emulsifying curcuminoids composition with enhanced bioavailability
US8329757B2 (en) * 2008-10-14 2012-12-11 Charlesson, Llc Curcumin analog compositions and related methods
CN101627969B (zh) * 2009-07-30 2011-06-29 浙江工业大学 一种姜黄素自乳化给药系统及其制备

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046978A1 (es) * 2017-09-05 2019-03-14 Universidad De Chile Método para obtener nanoestructuras con carotenoides y nanoestructuras obtenidas
RU2808324C2 (ru) * 2019-02-11 2023-11-28 Джозеф ХАЛСТЕД Терапевтически применимые высокодозированные безводные растворы куркуминоидов

Also Published As

Publication number Publication date
EP2616053A2 (en) 2013-07-24
US20130225689A1 (en) 2013-08-29
WO2012035480A2 (en) 2012-03-22
WO2012035480A3 (en) 2012-07-05
EP2616053B1 (en) 2016-11-02
EP2616053A4 (en) 2014-01-15
US9474727B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
ES2616022T3 (es) Composiciones farmacéuticas de curcumina
HRP20140445T1 (hr) Farmaceutski sastav za inhibitor proteaze virusnog hepatitisa c
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
ES2617683T3 (es) Composiciones oftálmicas basadas en ácidos grasos Omega-3 y Omega-6 poliinsaturados
RU2012130421A (ru) Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
MX2017009489A (es) Composicion auto-emulsionante de acido graso ?3.
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
RU2011148140A (ru) Самомикроэмульгирующаяся оральная фармацевтическая композиция, содержащая гидрофильное лекарственное средство, и способ ее приготовления
JP2013515018A5 (es)
PE20080390A1 (es) Composiciones antioxidantes liquidas monofasicas solubles en lipidos y procesos para elaborar las composiciones
RU2013126259A (ru) Фармацевтическая композиция таксоидов
RU2011139638A (ru) Сублингвальная фармацевтическая композиция, содержащая нейтральное масло
RU2015134141A (ru) Композиции твердых растворов и их применение при хроническом воспалении
CL2013002611A1 (es) Composicion de complejo oral que contiene un nucleo de ester de acido graso omega-3,una primera capa hidrofobica, una segunda capa que contiene: i) rosuvastatina y ii) alcohol polivinilico, copolimero alcohol polivinilico-polietilen glicol o mezclas; metodo de preparacion.
PH12016500100B1 (en) Self-emulsifying composition of omega3 fatty acid
RU2018136873A (ru) Сложные эфиры для лечения офтальмологических воспалительных заболеваний
CO6501136A2 (es) Composiciones que comprenden una mezcla de aceite de ácido graso y un tensoactivo, y métodos y usos de las mismas
JP2012524771A5 (es)
JP2014509655A5 (es)
CA2864118A1 (en) Formulations of bendamustine
RU2015144013A (ru) Липидные композиции рацекадотрила
MX2015011074A (es) Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
RU2015102597A (ru) Липидные композиции рацекадотрила
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
ES2561207T3 (es) Emulsión grasa para alimentar artificialmente a pacientes gravemente enfermos de cuidados intensivos